[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100466218":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":20,"locations":31,"responsibleParty":74,"collaborators":76,"id":87,"slug":88,"hasResults":89,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":10,"eligibilityCriteria":93,"healthyVolunteers":89,"sex":94,"minAge":95,"maxAge":10,"enrollmentInfo":96,"targetDuration":10,"studyType":99,"phases":10,"briefSummary":100,"conditions":101,"keywords":103,"overallStatus":34,"whyStopped":10,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":115},{"fullName":5,"class":6},"The HIV Netherlands Australia Thailand Research Collaboration","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"HDV cohort",null,"Chronic Hepatitis B (HBsAg+) with cirrhosis (APRI \\>1.5, FIB-4 \\> 3.25, Fibroscan \\> 12.5, imaging), PWID with HBV, HIV\u002FHBV, HBV\u002FHCV, aged 18 years and older",[13,17],{"name":14,"affiliation":15,"role":16},"Anchalee Avihingsanon, MD, PhD","Thai Red Cross AIDS Research Centre","PRINCIPAL_INVESTIGATOR",{"name":18,"affiliation":19,"role":16},"Pisit Tangkijvanich, MD","Biochemistry, Faculty of Medicine, Chulalongkorn University",[21,27],{"name":22,"role":23,"phone":24,"phoneExt":25,"email":26},"Chatsuda Auchieng","CONTACT","6626523040","118","chatsuda.a@hivnat.org",{"name":28,"role":23,"phone":24,"phoneExt":29,"email":30},"Pirapon J Ohata, BSc","147","juneohata4@gmail.com",[32,50,58,66],{"facility":33,"status":34,"city":35,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"HIV-NAT, Thai Red Cross - AIDS Research Centre","RECRUITING","Bangkok","10330","Thailand","TH",{"type":40,"coordinates":41},"Point",[42,43],100.50144,13.75398,{"lat":43,"lon":42},[46,49],{"name":14,"role":23,"phone":24,"phoneExt":47,"email":48},"107","anchaleea2009@gmail.com",{"name":22,"role":23,"phone":24,"phoneExt":25,"email":26},{"facility":51,"status":34,"city":35,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":52,"geoPoint":54,"contacts":55},"King memorial Chulalongkorn hospital",{"type":40,"coordinates":53},[42,43],{"lat":43,"lon":42},[56],{"name":18,"role":23,"phone":10,"phoneExt":10,"email":57},"pisittkvn@gmail.com",{"facility":59,"status":34,"city":35,"state":35,"zip":10,"country":37,"countryCode":38,"cosmosGeoPoint":60,"geoPoint":62,"contacts":63},"Siriraj Hospital, Mahidol University",{"type":40,"coordinates":61},[42,43],{"lat":43,"lon":42},[64],{"name":65,"role":23,"phone":10,"phoneExt":10,"email":10},"Tawesak Tanwandee, MD",{"facility":67,"status":34,"city":35,"state":35,"zip":10,"country":37,"countryCode":38,"cosmosGeoPoint":68,"geoPoint":70,"contacts":71},"Taksin Hospital",{"type":40,"coordinates":69},[42,43],{"lat":43,"lon":42},[72],{"name":73,"role":23,"phone":10,"phoneExt":10,"email":10},"Supunee Jirajariyavej, MD",{"type":75,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[77,79,80,82,84],{"name":78,"class":6},"King Chulalongkorn Memorial Hospital",{"name":15,"class":6},{"name":81,"class":6},"Siriraj Hospital",{"name":67,"class":83},"UNKNOWN",{"name":85,"class":86},"Gilead Sciences","INDUSTRY","100466218","thailand-hdv-cohort-100466218",false,"NCT05350865","Thailand HDV Cohort","Prevalence, Risk Factor and Clinical Significance of Hepatitis D Virus Infection Among Targeted High Risk Population in Thailand: Nationwide Survey 2022-2024","Inclusion Criteria:\n\n1. Male or female, aged 18 years and older\n2. Chronically-infected with HBV, as defined by:\n\n   Positive Hepatitis B surface antigen HBsAg) or HBV DNA result with a subsequent positive HBsAg or HBV DNA result at least 6 months after first positive result\n3. Provide signed and dated informed consent form.\n\nExclusion Criteria:\n\nNon chronic HBV","ALL","18 Years",{"count":97,"type":98},3152,"ESTIMATED","OBSERVATIONAL","There is very limited data of HDV in Thailand. As both HDV and HIV can accelerate the HBV course and increased the risk of death, particularly, among those with low CD4 cells\u002Fcount, therefore, HDV burden in this special population is unmet need. Therefore, this study plans to perform a nationwide survey of the prevalence and predictor of HDV among people uses drugs (PWID) with and without HIV, HBV\u002FHIV (MSM vs non MSM), HBV related cirrhosis. Findinds from this study will provide the scientific community to understand how important HDV is among HBV patients, this could be used to develop strategies for HDV screening and treatment",[102],"HDV",[104,102,105,37],"HBV","cirrhosis","2024-09-30",{"date":108,"type":109},"2024-10-02","ACTUAL",{"date":111,"type":109},"2023-01-30",{"date":113,"type":98},"2025-05",{"name":5,"class":6},4]